Gender of offspring and maternal risk of invasive epithelial ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2314-2320

  Baik, Inkyung ^a   Lambe, Mats ^b   Liu, Qin ^a   Cnattingius, Sven ^b   Mucci, Lorelei A ^d,e   Riman, Tomas ^f,g   Ekbom, Anders ^c   Adami, Hans Olov ^b,e   Hsieh, Chung Cheng ^a,b,e  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f Center for Clinical Research   (Sweden)

^g FALUN HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; FEMALE; GENDER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATERNAL WELFARE; MOTHER CHILD RELATION; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGENY; SEX RATIO; SWEDEN;

ADOLESCENT; ADULT; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HORMONES; HUMANS; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PARITY; PREGNANCY; RISK FACTORS; SEX FACTORS; SEX RATIO; SWEDEN;

EID: 38849136452     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0645     Document Type: Article

References (58)

1. Negri E, Franceschi S, Tzonou A, et al. Pooled analysis of 3 European case-control studies. I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-6.
2. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203.
3. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-4.
4. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994;140:585-97.
5. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995;62:678-84.
6. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:284-90.
7. Wittenberg J, Cook LS, Rossing MA, Weiss NS. Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer. Epidemiology 1999;10:761-3.
8. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001;84:714-21.
9. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002;156:363-73.
10. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-38.
11. Obiekwe BC, Chard T. Human chorionic gonadotropin levels in maternal blood in late pregnancy: relation to birthweight, sex and condition of the infant at birth. Br J Obstet Gynaecol 1982;89:543-6.
12. Troisi R, Potischman N, Roberts J, et al. Association of maternal and umbilical cord hormone concentrations with maternal, gestational and neonatal factors (United States). Cancer Causes Control 2003;14:347-55.
13. Sowers SG, Reish RL, Burton BK. Fetal sex-related differences in maternal serum α-fetoprotein during the second trimester of pregnancy. Am J Obstet Gynecol 1983;146:786-9.
14. Gierach GL, Modugno F, Ness RB. Gender of offspring and maternal ovarian cancer risk. Gynecol Oncol 2006;101:476-80.
15. Albrektsen G, Heuch I, Thoresen S, Kvale G. Twin births, sex of children and maternal risk of ovarian cancer: a cohort study in Norway. Br J Cancer 2007;96:1433-5.
16. Liu Q, Lambe M, Baik I, et al. A prospective study of the transient decrease in ovarian cancer risk following childbirth. Cancer Epidemiol Biomarkers Prev 2006;15:2508-13.
17. Kumle M, Weiderpass E, Braaten T, Adami HO, Lund E. Risk for invasive ovarian cancer and borderline ovarian tumours following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer 2004;90:1386-91.
18. Balmana J, Diez O, Campos B, et al. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon? Breast Cancer Res Treat 2005;92:273-7.
19. Chenevix-Trench G, Sinilnikova OM, Suthers G, et al. kConFab Investigators. Ratio of male to female births in the offspring of BRCA1 and BRCA2 carriers. Fam Cancer 2005;4:73-5.
20. Gronwald J, Byrski T, Huzarski T, Narod SA, Lubinski J. Male to female ratio among offspring of BRCA1 mutation carriers. Breast Cancer Res Treat 2006;97:113-4.
21. Rothman KJ, Liess J. Gender of offspring after oral-contraceptive use. N Engl J Med 1976;295:859-61.
22. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
23. Stadel BV. The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975;123:772-4.
24. Kelsey JL, Whittemore AS. Epidemiology and primary prevention of cancers of the breast, endometrium, and ovary. A brief overview. Ann Epidemiol 1994;4:89-95.
25. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
26. Lambe M, Wuu J, Rossing MA, Hsieh CC. Twinning and maternal risk of ovarian cancer. Lancet 1999;353:1941.
27. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004;83:783-95.
28. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005;14:98-107.
29. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
30. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol 2005;26:383-5.
31. Lacey JV, Jr., Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006;98:1397-405.
32. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
33. Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 2003;104:636-42.
34. Silva EG, Tornos C, Fritsche HA, Jr., et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997;10:879-83.
35. Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944-50.
36. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6.
37. Yu S, Lee M, Shin S, Park J. Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 2001;82:445-51.
38. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
39. Yen SSC, Jaffe RB, Barbieri RL. Reproductive endocrinology: physiology, pathophysiology, and clinical management. 4th ed. Philadelphia: W.B. Saunders; 1999; p. 768-70.
40. Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ. Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 2002;78:1096-9.
41. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999;51:34-41.
42. Lukanova A, Lundin E, Toniolo P, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002;101:549-54.
43. Gol M, Altunyurt S, Cimrin D, Guclu S, Bagci M, Demir N. Different maternal serum hCG levels in pregnant women with female and male fetuses: does fetal hypophyseal-adrenal-gonadal axis play a role? J Perinat Med 2004;32:342-5.
44. Boroditsky RS, Reyes FI, Winter JS, Faiman C. Serum human chorionic gonadotropin and progesterone patterns in the last trimester of pregnancy: relationship to fetal sex. Am J Obstet Gynecol 1975;121:238-41.
45. Steier JA, Myking OL, Bergsjo PB. Correlation between fetal sex and human chorionic gonadotropin in peripheral maternal blood and amniotic fluid in second and third trimester normal pregnancies. Acta Obstet Gynecol Scand 1999;78:367-71.
46. Gol M, Guclu S, Demir A, Erata Y, Demir N. Effect of fetal gender on maternal serum human chorionic gonadotropin levels throughout pregnancy. Arch Gynecol Obstet 2005;273:90-2.
47. Hercz P, Kazy Z, Siklos P, Ungar L. Quantitative comparison of serum steroid and peptide hormone concentrations in male and female fetuses in the maternal-fetoplacental system during the 28th-40th weeks of pregnancy. Eur J Obstet Gynecol Reprod Biol 1989;30:201-4.
48. Meulenberg PM, Hofman JA. Maternal testosterone and fetal sex. J Steroid Biochem Mol Biol 1991;39:51-4.
49. Dawood MY, Saxena BB. Testosterone and dihydrotestosterone in maternal and cord blood and in amniotic fluid. Am J Obstet Gynecol 1977;129:37-42.
50. Maccoby EE, Doering CH, Jacklin CN, Kraemer H. Concentrations of sex hormones in umbilical-cord blood: their relation to sex and birth order of infants. Child Dev 1979;50:632-42.
51. al-Nuaim AR, Abdullah MA, Stevens B, Zain M. Effect of gender, birth weight and gestational age on serum 17-hydroxyprogesterone concentration and distribution among neonates in Saudi Arabia. Indian J Pediatr 1995;62:605-9.
52. Godo B, Visser HK, Degenhart HJ. Plasma 17-OH-progesterone in fullterm and preterm infants at birth and during the early neonatal period. Horm Res 1981;15:65-71.
53. Verhaeghe J, Van Bree R, Van Herck E, Laureys J, Bouillon R, Van Assche FA. C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in umbilical cord serum: correlations with birth weight. Am J Obstet Gynecol 1993;169:89-97.
54. Bernstein IM, Goran MI, Copeland KC. Maternal insulin sensitivity and cord blood peptides: relationships to neonatal size at birth. Obstet Gynecol 1997;90:780-3.
55. Coutant R, Boux de Casson F, Douay O, et al. Relationships between placental GH concentration and maternal smoking, newborn gender, and maternal leptin: possible implications for birth weight. J Clin Endocrinol Metab 2001;86:4854-9.
56. Vatten LJ, Nilsen ST, Odegard RA, Romundstad PR, Austgulen R. Insulin-like growth factor I and leptin in umbilical cord plasma and infant birth size at term. Pediatrics 2002;109:1131-5.
57. Chen RJ, Lin YH, Huang SC. Fetal sex and maternal α-fetoprotein concentration at late normal singleton pregnancies. Acta Obstet Gynecol Scand 1994;73:192-4.
58. Szabo M, Veress L, Munnich A, Papp Z. Maternal age-dependent and sex-related changes of gestational serum α-fetoprotein. Fetal Diagn Ther 1995;10:368-72.